dc.contributor.author | Bushiha, Aisha Hamdi | |
dc.date.accessioned | 2019-02-27T09:13:27Z | |
dc.date.available | 2019-02-27T09:13:27Z | |
dc.date.issued | 2018-05-05 | |
dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/535 | |
dc.description | human papillomavirus which are a group of more than 200 related viruses. More than 40 types can be easily
spread through direct sexual contact, other types of virus are responsible for non-genital warts, which are not
sexually transmitted. HPV is the most common viral infection of the reproductive tract and is the cause of a
range of conditions in both men and women, including precancerous lesions that may progress to cancer.
Although the majority of HPV infections do not cause symptoms and resolve spontaneously, persistent
infection with HPV may result in disease. In women, persistent infection with specific HPV types (most
frequently HPV-16 and HPV-18) may lead to precancerous lesions which, if untreated, may progress to
HPV infection is also associated with oropharyngeal and anogenital cancers and other (1) cervical cancer.
conditions in men and women. HPV. HPV vaccination can reduce the risk of infection by the HPV types
targeted by the vaccine. The Food and Drug Administration (FDA) has approved three vaccines to prevent
HPV infection: Gardasil®, Gardasil® 9, and Cervarix®. These vaccines provide strong protection against
new HPV infections, but they are not effective at treating established HPV infections or disease caused by
HPV | en_US |
dc.description.abstract | The aim of this report is to discuss the Pathogenicity of human papilloma virus and the use of vaccines
against it. | en_US |
dc.language.iso | en | en_US |
dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Human Papillomavirus (HPV) Vaccines | en_US |
dc.type | Other | en_US |